Data as of Jul 25
| +0.88 / +2.30%|
Receptos, Inc. is a biopharmaceutical company. It discovers, develops and commercializes innovative therapeutics for immune disorders. The company clinical pipeline includes RPC1063 and RPC4046. The RPC1063 is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The RPC4046 developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. Receptos was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.
|Faheem Hasnain||President, Chief Executive Officer & Director|
|Graham K. Cooper||CFO, Head-Investor & Media Relations|
|David A. Hinkle||CAO, Finance Director & Controller|
|Robert J. Peach||Chief Scientific Officer|
|Marcus F. Boehm||Chief Technology Officer|